Use of morphine derivatives as medicaments for the treatment of neuropathic problems
AssigneeGruenenthal GmbH
InventorsStephan Wnendt, Wolfgang Strassburger, Helmut Buschmann, Elke Reiss-Mueller, Thomas Krueger
Life of this patent
Estimating the term…
Abstract
A method for agonizing or antagonizing the ORL1 (opioid receptor-like) receptor of the nociceptin/orphanin FQ ligand ORL1 receptor system using a morphinan compound of the general formula I or derivatives thereof. Also disclosed are methods for treating neuropathic pain and/or anxiolysis and/or depression and/or diuresis and/or urinary incontinence and/or hypotension and or hypertension and/or senile dementia and/or Alzheimer's disease and/or general cognitive disfunctions an/or tinnitus and/or impaired hearing and/or epilepsy and/or obesity and/or cachexia.
Claims13
A method for agonizing or antagonizing the ORL1 (opioid receptor-like) receptor of the nociceptin/orphanin FQ ligand ORL1 receptor system, the method comprising administering, to a cell comprising said receptor system, an effective amount of a composition comprising a morphinan compound of formula I:
- wherein
- R1 denotes H, a C1-4 alkyl group or a C2-4 alkenyl group;
- R2 denotes H, a C1-18 alkyl group, a C2-18 alkenyl group, a heterocyclyl group or an aryl group;
- R3 denotes a C1-18 alkyl group, a C2-18 alkenyl group, a C3-7 cycloalkyl, aryl or heterocyclyl group bound via a C1-4 alkylene group, or a C3-7 cycloalkyl, aryl or heterocyclyl group bound via a C2-4 alkenylene group;
- R4 denotes H, a C1-18 alkyl group, a C2-18 alkenyl group, a C3-7 cycloalkyl or aryl group bound via a C1-4 alkylene group, or a C3-7 cycloalkyl or aryl group bound via a C2-4 alkenylene group, and
- X denotes O or NR5 where
- R5 denotes H, a C1-18 alkyl group, a C2-18 alkenyl group, a C3-7 cycloalkyl, aryl or heterocyclyl group bound via a C1-4 alkylene group, or a C3-7 cycloalkyl, aryl or heterocyclyl group bound via a C2-4 alkenylene group,
- or an enantiomer, diastereomer, or physiologically compatible salt thereof.
A method for the treatment of at least one condition selected from the group consisting of neuropathic pain, anxiolysis, depression, diuresis, urinary incontinence, hypotension, hypertension, senile dementia, Alzheimer's disease, general cognitive dysfunctions, tinnitus, impaired hearing, epilepsy, obesity, and cachexia, the method comprising administering an effective amount of a compound of formula I:
- wherein
- R1 denotes H, a C1-4 alkyl group or a C2∝alkenyl group;
- R2 denotes H, a C1-18 alkyl group, a C2-18 alkenyl group, a heterocyclyl group or an aryl group;
- R3 denotes a C1-18 alkyl group, a C2-18 alkenyl group, a C3-7 cycloalkyl, aryl or heterocyclyl group bound via a C1-4 alkylene group, or a C3-7 cycloalkyl, aryl or heterocyclyl group bound via a C2-4 alkenylene group;
- R4 denotes H, a C1-18 alkyl group, a C2-18 alkenyl group, preferably a C2-10 alkenyl group, a C3-7 cycloalkyl or aryl group bound via a C1-4 alkylene group, or a C3-7 cycloalkyl or aryl group bound via a C2-4 alkenylene group, and
- X denotes O or NR5 where
- R5 denotes H, a C1-18 alkyl group, a C2-18 alkenyl group, a C3-7 cycloalkyl, aryl or heterocyclyl group bound via a C1-4 alkylene group, or a C3-7 cycloalkyl, aryl or heterocyclyl group bound via a C2-4 alkenylene group,
- or an enantiomer, diastereomer, or physiologically compatible salt thereof.
Dependencies are inferred from the claim text.